Imara Presents Preclinical Data on IMR-261 at the American Society of Hematology (ASH) Annual Meeting 2021
Retrieved on:
Tuesday, December 14, 2021
Fetal hemoglobin, HBF, Thalassemia, U.S. Securities and Exchange Commission, Heart failure, Company, Sickle cell disease, Tumor necrosis factor, Oxidative stress, PDE9, RBC, Private Securities Litigation Reform Act, Nasdaq, Hemolysis, Hemoglobinopathy, COVID-19, Iron overload, Volatile organic compound, PAH, Pediatrics, VOC, Research, Goal, Inflammation, Patient, NF, Lists of diseases, Focal segmental glomerulosclerosis, Therapy, Security (finance), FSGS, Nucleated red blood cell, Hypertensive emergency, Program, Erythropoiesis, Augusta University, GLOBE, ASH, Heart failure with preserved ejection fraction, SCD, Mouse, Society, Complexa, Vaccine, Pharmaceutical industry, Palladium, NFE2L2, Townes, HB
BOSTON, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat subjects suffering from rare inherited genetic disorders of hemoglobin and other serious diseases, today announced the presentation of data from its nuclear factor erythroid 2-related factor 2 (Nrf2) activator program, IMR-261, at the American Society of Hematology (ASH) Annual Meeting, held December 11-14, 2021.
Key Points:
- Preclinical studies evaluated the impact of IMR-261 using in-vitro cell cultures and in-vivo mouse models of sickle cell disease (SCD) and beta-thalassemia.
- Furthermore, an approximately 3-fold increase in F-cells was seen in both high dose and low dose groups when compared to placebo.
- We are pleased to report robust data with IMR-261 in validated preclinical models of SCD and beta-thalassemia, said Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara.
- In preclinical sickle cell disease models, IMR-261 significantly increased HbF and F-cells, improved hemolytic markers, and decreased vaso-occlusive crises.